Clinical significance of Toxoplasma gondii in immunocompetent cats by Lau, Wing Yin
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical significance of Toxoplasma 
gondii in immunocompetent cats 
Wing Yin Lau 
 
 
 
 
Uppsala 
2018 
Veterinärprogrammet, examensarbete för kandidatexamen 
 
Delnummer i serien: 2018:53 
Fakulteten för veterinärmedicin 
och husdjursvetenskap 
Institutionen för biomedicin och veterinär 
folkhälsovetenskap 
 
  
Clinical significance of Toxoplasma gondii in 
immunocompetent cats 
 
 
 
Wing Yin Lau 
 
 
Handledare:  Giulio Grandi, Institutionen för biomedicin och veterinär 
folkhälsovetenskap (BVF), enheten för parasitologi 
 
 
Examinator:  Maria Löfgren, institutionen för biomedicin och veterinär 
folkhälsovetenskap (BVF) 
Omfattning: 15 hp 
Nivå och fördjupning: Grundnivå, G2E 
Kurstitel: Självständigt arbete i veterinärmedicin 
Kurskod: EX0700 
Program/utbildning: Veterinärprogrammet 
 
Utgivningsort: Uppsala 
Utgivningsår: 2018 
Serienamn: Veterinärprogrammet, examensarbete för kandidatexamen 
Delnummer i serien: 2018:53 
Elektronisk publicering: http://stud.epsilon.slu.se 
 
Nyckelord: Toxoplasma gondii, toxoplasmos, katt, immunokompetent  
Key words: Toxoplasma gondii, toxoplasmosis, cat, immunocompetent 
 
Sveriges lantbruksuniversitet 
Swedish University of Agricultural Sciences 
Fakulteten för veterinärmedicin och husdjursvetenskap 
Institutionen för biomedicin och veterinär folkhälsovetenskap 
 
 
  
CONTENT 
Sammanfattning  ........................................................................................................................ 1 
Summary  ................................................................................................................................... 2 
Introduction  ............................................................................................................................... 3 
Material and method  .................................................................................................................. 3 
Literature review  ....................................................................................................................... 3 
Background of the parasite  ............................................................................................ 3 
Immune response to T. gondii infection ......................................................................... 4 
Toxoplasmosis ................................................................................................................ 5 
Diagnostic method .......................................................................................................... 6 
Treatment  ...................................................................................................................... 7 
Cases of clinical toxoplasmosis in immunocompetent cats ........................................... 7 
Discussion  ................................................................................................................................. 8 
Challenges of antemortem diagnosis and clinical significance  ..................................... 8 
Prevention and control  .................................................................................................. 9 
Future studies ............................................................................................................... 10 
Conclusion .................................................................................................................... 10 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
SAMMANFATTNING 
Toxoplasma gondii är en intracellulär parasit som har kattdjur som sin slutgiltiga värd och alla 
varmblodiga däggdjur och fåglar som mellanvärd. De flesta infekterade värdarna visar inga 
symptom, speciellt katter som kan utveckla en långvarig immunitet efter den första 
infektionen. Klinisk toxoplasmos är sällsynt och förekommer vanligt hos patienter som är 
immunnedsatta. Detta faktum kan göra att man är mindre uppmärksam på hur T. gondii kan 
påverka katterna kliniskt generellt, särskilt för de som är immunokompetenta. Klinisk 
toxoplasmos är en allvarlig sjukdom som kan vara dödlig för katter som inte får adekvat 
behandling i tid då det kan utvecklas aggressivt. Symtomen varierar och är vanligtvis 
ospecifika; några kliniska fall sammanfattas i denna uppsats. De flesta tester ger inte 
avgörande resultat för att ställa en slutgiltig diagnos, och veterinärer misstänker inte 
sjukdomen tillräckligt tidigt för att testa för parasiten. Dessa faktorer utgör en stor utmaning 
för kliniker att göra en tidig och korrekt diagnos som är nyckeln till behandling. 
Nyckelord: Toxoplasma gondii, toxoplasmos, katt, kattdjur, immunokompetent 
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SUMMARY 
Toxoplasma gondii is an obligate intracellular parasite, with felines as its definitive host and 
all warm-blooded mammals and birds as intermediate hosts. It is known that most infected 
hosts are asymptotic, especially cats are supposed to be able to develop a long-term immunity 
after first time infection. Clinical toxoplasmosis is rare and occurs in patients that are usually 
immunosuppressed, this fact can make one be less alert about the significance of how T. 
gondii can potentially affect cats clinically in general, especially for those that are 
immunocompetent. Clinical toxoplasmosis is a serious disease that can be fatal to cats that do 
not receive adequate treatment in time as it can progress aggressively. The symptoms vary 
and are usually nonspecific; a few cases will be summarized in this paper. Most tests, when 
conducted alone, do not give conclusive information to make a definitive diagnosis. As 
toxoplasmosis is usually not included in the list of differential diagnosis when it comes to 
acute cases, because it occurs so rarely, so the running of diagnostic tests is often delayed. 
These factors pose a great challenge for clinicians to make an early and correct diagnosis 
which is the key for treatment.  
 
Keyword: Toxoplasma gondii, toxoplasmosis, cat, feline, immunocompetent  
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INTRODUCTION 
Toxoplasm gondii, a zoonotic intracellular protozoan, can infect all mammals including 
human or birds (Taylor et al., 2007). The definitive hosts are cats and other feline mammals 
in which they reproduce sexually and produce oocysts which are excreted via faeces to the 
environment. Intermediate hosts are those in which the parasites develop to tissue cysts and 
await to complete the life cycle when the infected tissue is ingested by their definitive host. 
Individuals can be infected by ingesting either infectious oocyst or tissue cyst in intermediate 
host. Infection by oocyst takes only as low as a few sporulated oocysts (Deplazes et al., 
2016). Cat can develop immunity for up to 6 years after the oocyst-shedding phase (Cenci-
Goga et al, 2011). 
 
T. gondii is an interesting parasite because of its ability to infect a wide range of species and it 
can be found worldwide, affecting 1/3 of the human population (Deplazes et al., 2016), both 
indicate superior survival ability and ease of transmission.   
 
Even though infection is common in cats (Hartmann et al., 2013) it is believed that clinical 
toxoplasmosis is rare, and it occurs most likely in young or immunosuppressed individuals 
(Deplazes et al. 2016). In this case the affected organs are usually the central nervous system 
(CNS), muscles, lungs and eyes (Hartmann et al., 2013). Rare occurrence of clinical 
toxoplasmosis on final and intermediate host is another survival advantage of the parasite as 
sick individual are less likely to help the parasite to complete its life cycle. However, can T. 
gondii have any clinical significance on immunocompetent cats? If so, how are they affected?  
 
The above-mentioned questions will be discussed and the clinical significance of 
toxoplasmosis in immunocompetent cats will be addressed below, and some cases of clinical 
toxoplasmosis will also be presented.  
 
MATERIAL AND METHOD  
The literature search was mainly done on Primo, the library search tool of the Swedish 
University of Agricultural Sciences. Key words like “cat”, “toxoplasma gondii”, 
“toxoplasmosis”, “feline”, “case report”, “vaccine”, “diagnostic methods” were used during 
article search and preferably if they were included in the titles of the articles. As the number 
of articles generated by the search is very large so only those with higher relevance were 
selected. Articles that are peer-reviewed and within 10 years were preferred but if an older 
article is highly relevant it would still be used and cited. Textbooks from previous 
immunology, parasitology and virology courses were also cited in this paper.  
 
LITERATURE REVIEW  
Background of the parasite  
T. gondii has an indirect life cycle, which consists of two parts, the enteroepithelial life cycle 
and the extraintestinal life cycle (Hartmann et al., 2013).  
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The enteroepithelial life cycle only happens in their definitive host – felines.  When a cat 
ingests tissue cysts from an intermediate host (e.g. rat), the cysts wall is broken down by the 
enzyme in the stomach and bradyzoites are released (Weiss & Kim, 2014). The bradyzoites 
are resistant to gastric juice (Weiss & Kim, 2014) and are able to reach the small intestine 
where they enter the epithelial cells of the intestine. They then go through merogony and 
gamogony to form oocyst (Hartmann et al., 2013). The oocysts are excreted to the 
environment via faeces. After being exposed to air and moisture the oocysts sporulate and 
become infectious (Hartmann et al., 2013). Each sporulated oocyst contains two sporocysts 
and each sporocyst contain four sporozoites (Taylor et al., 2007). Sporulated oocysts can 
survive in moist soil for 1-1.5 years and cool fresh water for 4.5 years (Deplazes et al., 2016, 
p.104). “Shedding of oocyst is more common in the latter half of the year in the northern 
hemisphere” (Hartmann et al., 2013, p.632). Cats can shed a large number of oocysts without 
showing any clinical sign (Dubey & Powell, 2013). As mentioned above, cats develop long-
term immunity after the shedding oocysts. Prepatent period lasts for 3-10 days if bradyzoites 
are ingested while 18 days or more if tachyzoites or sporozoites are ingested (Weiss & Kim, 
2014).  
 
Extraintestinal life cycle takes place in all the susceptible species, all mammals and birds, 
even in felines (Hartmann et al., 2013). When oocysts are ingested, they reach the small 
intestine and hatches so the sporozoites are released (Hartmann et al., 2013). Sporozoites 
penetrate and invade intestinal cell and even macrophages (Tizard, 2012), they go asexual 
reproduction called endodyogeny and transform into tachyzoites. Tachyzoites can multiply in 
almost any cell and their rapid intracellular replication can cause necrosis of the infected 
tissues, it can also disseminate via blood and lymph during active infection and invade other 
cells (Cohen et al., 2016). Eventually they transform into bradyzoites and modifies the 
membrane of the parasitophorous vacuole to a cyst wall and change the metabolism. 
Bradyzoites multiply slowly, compared to tachyzoites, by endodyogeny and they encyst. Cyst 
wall and matrix develop as the tissue cysts mature and they are important for protecting the 
bradyzoites from the environment and the host immune response by serving as a barrier 
(Weiss & Kim, 2014). Tissue cysts are most often found in visceral organs, musculature and 
neural tissue and they can persist in the host for years (Deplazes et al., 2016). When the 
intermediate host is consumed by the definitive or another intermediate host, the tissue cyst 
wall will be broken down in the stomach and bradyzoites are released to infect the intestine 
(Hartmann et al., 2013). In definitive hosts the bradyzoites will then replication sexually as 
mentioned above in the enteroepithelial cycle and their life cycle is completed. Even cats can 
be infected by sporulated oocysts and the infection proceed as extraintestinal life cycle, they 
are more susceptible to tissue cyst (bradyzoites) when they consume an infected prey (Turner 
et al., 2013). 
 
Immune response to T. gondii infection 
Upon infection, both innate and adaptive immunity respond to T. gondii (Deplazes et al., 
2016).  
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The innate immune response starts when pathogen-associated molecular pattern (PAMPs), in 
this case, profilin on the protozoa induce effector cell reactions (macrophages, neutrophils and 
others) by binding to Toll-like receptors (TLR) (Deplazes et al., 2016). Interleukin-12 (IL-12) 
and interferon-γ (IFN-γ) are the main cytokines involved in the innate response, both 
cytokines activated NK cells and macrophage to control the parasite. In an activated 
macrophage the intracellular parasites can be killed by lysosome-vacuole fusion (Tizard, 
2012). 
 
According to Tizard (2012), the adaptive immune system responds to protozoa infection with 
both antibody- and cell-mediated immune response; antibody response targets mainly control 
parasite in blood and tissue fluid while cell-mediated response works against intracellular 
parasites. Antibodies can potentially opsonize, agglutinate, immobilize and even inhibit 
parasite division but they have no impact over the intracellular form of T. gondii and therefore 
the cell-mediated immune response is the more effective response to combat this protozoon 
(Tizard, 2012). T. gondii penetrate cells with a system called “gliding” and they reside in a 
parasitophorous vacuole, this cell invasion does not trigger normal phagosome formation or 
maturation, and therefore the parasitophorous vacuole does not fuse with lysosome which 
makes it possible for T. gondii to survive in the cell and replicate without antibodies attacking 
them (Tizard, 2012). However, cytotoxic T cell can kill tachyzoites and T. gondii infected 
cells (Tizard, 2012).  
 
T. gondii is found to be able to actively manipulate the biology of the hosts cell, especially the 
intracellular signalling of the immune system. For example, it can interfere with the apoptosis 
in infected macrophages and it can even block the signalling of IFN-γ and TLR (Weiss & 
Kim, 2014), which is important for the activation of the cell-mediated immune response as 
mentioned above. According to Rang et al. (2016, p. 658) “T. gondii has a highly virulent 
replicating stages and to ensure its hosts’ survival it can stimulate the production of IFN-γ and 
modulate the cell-mediated response to promote encystment of the parasite in the tissues”. 
Additionally, the immune surveillance in CNS, where the tissue cysts are usually formed, is 
different from the one present in other tissues (Fabry et al. 1994 see Kim & Boothroyd 2005), 
which is another strategy for the parasite to persist in the hosts for life. Furthermore, 
bradyzoite-specific surface antigens “appear to be poorly or not at all immunogenic in 
infection” (Kim & Boothroyd, 2005, p.8039) which allows bradyzoites to persist in their 
immunocompetent hosts for a long time as they can evade the immune system. 
 
Toxoplasmosis 
Toxoplasmosis is the disease caused by T. gondii. In a study published by Dubey and 
Carpenter (1993), clinical data of 100 cats that had histologically verified toxoplasmosis were 
examined and they found that fever, dyspnoea, polypnea and abdominal discomfort were the 
most common clinical signs. The age of the cats included in their study ranged from 2 weeks 
old to 16 years old (mean age 4 years old).  
 
There are some stress conditions that can induce bradyzoite development from tachyzoites 
and they are temperature stress, pH stress, and certain chemical stress (e.g. IFN-γ and NO) 
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(Weiss & Kim, 2014). Conversely, the conversion of bradyzoites to tachyzoites can be 
induced in vitro by the removal of stress factor (Deplazes et al., 2016). This finding can lead 
to the speculation that the absence of stress factor could be contributing to the reactivation of 
the chronic infection which is dominated by bradyzoites residing in tissue cysts into an active 
infection which is dominated by tachyzoites (Weiss & Kim, 2014). Immunosuppression is 
said to be able to induce tissue cyst rupture and thereby the multiplication and dissemination 
of tachyzoites (Barrs et al. 2006). As immune response from the hosts can put the parasite 
under stress so for those immunodeficient hosts the bradyzoites can probably be more likely 
to convert to tachyzoites compared to an immunocompetent individual, which leads to active 
toxoplasmosis. In a study done by Barrs et al. (2006), two cases of clinical toxoplasmosis in 
cats were presented and both cats had been treated with therapeutic doses of cyclosporine (an 
immunosuppressant medication) prior to the disease. “Reactivation of latent Toxoplasma 
gondii infection secondary to cyclosporine-induced immunosuppression was considered likely 
in both cases” (Barrs et al., 2006, p. 30).  
 
One can suspect that FIP can increase the risk of clinical toxoplasmosis as FIP virus infection 
cause T-helper cells depletion due to the virus cytopathic effect and replication in T-helper 
lymphocytes which in turn causes deterioration of cell-mediated immunity, the main defence 
again T. gondii (Quinn, 2011). However, according to Dubey and Prowell (2013), there are 
only a few cases of clinical toxoplasmosis in cats with FIV infection.  
 
As mention above in the introduction, cats usually can develop a firm immunity against the 
parasite and it should be enough to control re-infection and oocyst excretion (Deplazes et al., 
2016).  
 
Clinical toxoplasmosis is rare and the reason behind it is not fully understood (Dubey & 
Prowell, 2013) and “it is unknown whether the severity of toxoplasmosis in 
immunocompetent hosts is due to the parasite strain, host variability, or to other factors” 
(Dubey & Prowell, 2013, p.158). Future research will be required to have a deeper 
understanding of the disease.  
 
Diagnostic methods 
There are different kinds of diagnostic methods available for T. gondii, including direct 
(faecal microscopy, molecular based approaches and DNA based approaches; Bajwa et al., 
2014) and indirect methods (serology). Faecal microscopy is based on the detection of oocysts 
in faecal samples of cats; this method is a common practice as it is cheap and does not require 
advanced equipment but since oocysts of similar size can be detected in cat faeces (i.e. 
Hammondia) (Daplaze et al., 2016), a molecular typing is required to confirm the diagnosis. 
Moreover, the oocyst-shedding phase is quite short, and some infected animals could be 
missed if using only faecal analyses. Examples for DNA based approaches are conventional 
polymerase chain reaction (PCR) and real time-PCR (Bajwa et al., 2014). “Tissue stages may 
be detected histologically, by means of immunohistology or DNA analyses in tissues samples 
taken post mortem” (Deplazes et al., 2016, p.107). Common diagnostic tools are represented 
by serology which can detect the presence of certain antibodies (e.g. Enzyme-linked 
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immunosorbent assay and indirect fluorescent antibody test) and stage specific 
immunoglobulins.  
 
Treatment 
According to the Swedish National Veterinary Institute (SVA) (2017) in Sweden, the 
recommendation of treatment for clinical toxoplasmosis in cat is clindamycin. The second 
choice of treatment would be a combination of sulphonamide and trimethoprim, but this 
combination is used when clindamycin gives side effects or insufficient effects or when CNS 
symptom is observed. The recommended dose of clindamycin is 12.5-2.5mg/kg body weight 
per oral every 12 hours for 2-4 weeks (Deplazes et al., 2016). However, bradyzoites in the 
tissue cysts are not affected by the chemotherapeutic agents used for treatment (Weiss & Kim, 
2014). 
 
 
Cases of clinical toxoplasmosis in immunocompetent cats 
Case 1 by Lindsay et al. (2010):  
The patient was a 10-year-old spayed Cornish Rex, it was vaccinated against feline 
panleukopenia virus, calicivirus, herpesvirus and feline immunodeficiency virus (FIV) within 
the past 12 months. It showed neurological symptoms mostly on the right side and they 
indicate problems with spinal cord segment C6-T2. T. gondii titres shows no indication of 
active toxoplasmosis but previous exposure. At post-mortem examination multifocal areas of 
necrosis and malacia were found at the cervical intumescence of the spinal cord. 
Immunohistochemical (IHC) staining confirmed the diagnosis of reactivated toxoplasmosis 
and it also showed tachyzoites free in the neutral parenchyma. A diagnose of marked 
segmental non-suppurative myelitis was made. Judging from the result of the examinations, 
the authors assumed that the CNS inflammation was caused by the reactivation of latent T. 
gondii infection rather than an acute one. In this case the cat had no known underlying cause 
of immunodeficiency or immunosuppression and it was vaccinated recently before the 
symptoms showed. It had been previously infected by T. gondii some time in her life and it 
has encyst in the CNS tissue. It has not affected the health of the cat until the reactivation of 
the infection, and even with intensive treatment no improvement was detected and therefore 
the cat was euthanised. As mentioned above, the reactivation of infection probably requires 
the absence of stress factor (e.g. immunity against T. gondii) but this case shows that it is 
possible for an immunocompetent individual to suffer from T. gondii infection reactivation.  
 
Case 2 by Nagel et al. (2013) 
A 10-year-old spayed, and apparently immunocompetent cat (good body condition and no 
history of immunosuppressing chemicals) was admitted due to sudden anorexia and 
polydipsia. She had severe abdominal pain and leukopenia. She was tested FIV, FeLV and 
FIP (at post-mortem examination) negative. Haematology and serum biochemistry implied 
severe hepatic injury or hepatitis with sepsis. Even with treatment the cat died 72 hours after 
admission. Necropsy confirmed severe hepatitis, pneumonia, subacute multifocal pancreatitis, 
multifocal encephalitis, multifocal myocarditis and mild nephritis with small fluid-filled cysts. 
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IHC staining confirmed the diagnosis of disseminated toxoplasmosis that bradyzoite-
containing cysts and free tachyzoites were found in most tissue. This case shows that not only 
can T. gondii cause clinical diseases in immunocompetent cats, it does not only limit to 
certain organs (CNS, muscle and lung as mentioned above) but disseminate to other organs 
and cause inflammations at the same time. The patient was treated with broad spectrum 
antibiotics amoxycillin-clavulanic acid against infectious hepatitis which was not the most 
appropriate choice of treatment in this case, this led to the speculation that if the correct 
diagnosis was made and the right antibiotics was given to the patient it would probably have 
increased the chance of survival.  
 
Case 3 by Cohen et al. (2016)  
22-month-old neutered cat with symptoms of lethargy, vomiting and reduced appetite, FIV 
and FeLV negative, was admitted. An irregular hyperechoic mass in the abdomen was 
detected with ultrasound. Although being treated symptomatically and with antibiotics the 
cat’s condition deteriorated and was euthanized.  Enlarged mesenteric lymph nodes were seen 
at the necropsy. Histopathology examination revealed extensive necrosis at the liver and the 
mesenteric lymph nodes. IHC confirmed the presence of T. gondii in the liver so a diagnosis 
of disseminated extraintestinal toxoplasmosis was made. The patient in this case is 
significantly younger than the two previous cases presented, it showed common signs of 
clinical toxoplasmosis, but they are very nonspecific, which makes it difficult to diagnose 
correctly.  
 
The above presented cases demonstrated that the infected cats are all apparently 
immunocompetent and their profile varies. Symptom-wise their health was affected in 
different ways but severely even though they suffered from the same disease and it was fatal. 
These cases showed the clinical significance of toxoplasmosis in the cat population; and 
demonstrate the difficulties of making correct diagnosis and giving the appropriate treatment.  
 
DISCUSSION 
Clinical toxoplasmosis is rare in cats, let alone it happens on the immunocompetent ones, but 
when it occurs it can adversely affect the health of the cats and can even be fatal. As T. gondii 
is so widely spread, the clinical importance of the parasite should be addressed which is also 
the aim of this study. 
 
Challenges of ante mortem diagnosis and clinical significance  
According to Cohen et al. (2016) ante mortem diagnosis of clinical toxoplasmosis is 
challenging as clinical signs are usually nonspecific and the disseminated form of the disease 
can be rapidly progressive which does not allow the clinicians much time.  A definitive 
diagnosis can be achieved by demonstration of T. gondii in the tissue associating with the 
inflammation, however it is usually done by necropsy (Lappin, 1999). It can be achieved ante 
mortem if bradyzoites or tachyzoite are found in tissues or effusion (Lappin, 1999).  
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Serological tests could be used to diagnose toxoplasmosis, but antibodies can be found in both 
healthy and sick cats (Cohen et al., 2016), therefore it is not possible to confirm a diagnosis 
solely base on these tests (Lappin, 1999). However, if a high IgM antibody titer or a 4-fold 
change in IgG titer is demonstrated it can lead to a presumptive diagnosis, combining with the 
presentation of clinical signs a more reliable diagnosis can be made (Cohen et al., 2016, 
p.485).  
 
Faecal analysis of oocyst is not very accurate as T. gondii oocysts have similar appearance as 
other coccidian species (Cohen et al., 2016). Pneumonia can be an indicator for feline 
toxoplasmosis as “it was documented in all fatal cases observed in a previous case series” 
(Cohen et al., 2016, p.483). 
 
The challenge is not only about the inconclusive result yielded from available tests but also 
the awareness of the disease from the clinicians. As clinical toxoplasmosis is so rare, and the 
symptoms are so non-specific, it is understandable that a veterinarian would not suspect this 
disease when a generally affected cat is admitted, and hence the delayed treatment. Clinicians 
must bear in mind that there is a possibility that toxoplasmosis can be the cause for a 
generally affected cat when the cat does not respond to treatments given for another disease.  
Regardless of the immunity competency of the cat, appropriate tests should be conducted as 
soon as possible for an early diagnosis and appropriate treatment in order to increase the 
chance of survival.  
 
Prevention and control 
As T. gondii has a wide range of susceptible hosts it is important to minimize the risk of 
infection and transmission of the parasite. As cats can shed a large number of oocysts when 
infected primarily and oocysts can survive in the environment for a long time, it is important 
for focus on minimizing the infection of cats as to reduce the contamination of the 
environment by oocysts. Domestic cats should be fed only with cooked or frozen meat, and 
one should try to prevent them from eating small mammals, which could be difficult if the 
cats are allowed to roam free outdoor (Deplazes et al., 2016). Cat owner should remove cat 
faeces from the litter box daily as oocysts require one day to sporulate and become infectious. 
“None of the commonly employed disinfectants kill T. gondii oocyst” (Dubey & Prowell, 
2013, p. 159) but they can be killed by being exposed to higher than 70 degrees Celsius. 
Persons including cat owners, clinicians or anyone who attend to infected cats should take 
appropriate hygiene measure and be aware of the consequences of this disease (Dubey & 
Prowell, 2013).  
 
According to Verma and Khanna (2013) the process of developing vaccine against feline 
shedding of oocyst is still ongoing and live vaccines are mostly used, a few vaccines 
mentioned in their studies function by either inhibiting the sexual development of T. gondii in 
cats or by making the parasite only develop partially in the intestines of cats. However, these 
vaccines target on minimizing the oocyst-shedding instead of preventing toxoplasmosis in 
cats. In a recent study done by Liu et al. (2017), they were testing a DNA vaccine with the 
gene TgSOD from T. gondii, and the vaccine triggered a stronger humoral and cellular 
10 
 
immune response in the treatment group compared to the control group. This development 
could become the foundation of a future vaccine that can prevent toxoplasmosis in cats. 
 
Future studies  
Future studies in this subject should focus on the underlying cause of clinical toxoplasmosis, 
exploring the possibility of a more virulent strain of T. gondii by genotyping those that are 
found on patient died from the disease, and how the immunity competency play a role in the 
development of diseases in healthy individuals. Easier, faster and more accurate tests and 
diagnostic method should also be developed to allow clinicians to make correct and early 
diagnosis and give appropriate treatment. An effective and economic vaccine targeting 
infection in cats should also be developed. 
 
Conclusion  
Toxoplasmosis is a serious disease for any mammals and cats and it is not only limited to 
immunodeficient individuals. Cats, being the definitive host of the parasite, are regarded as 
low risk individuals for the disease as they are supposed to be able to develop a long-term 
immunity against the parasite. However, they are just as susceptible as any other potential 
hosts. This study has addressed the clinical significance of toxoplasmosis in 
immunocompetent cats and the difficulties of diagnosis. Hopefully this will raise awareness 
and encourage future research on this subject.  
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